Podcasts about genomic testing

Join us as we learn more about this fourth-generation farm, Thiele Dairy of Clearwater, Nebraska. Bill Thiele shares his family's journey into dairy farming and how they have scaled their existing farm site to a nearly 3,000-cow milking herd. Utilizing Ultraplus™ gender-sorted semen, Vision+™ genomic testing and elevating their level of genetics through the STgenetics® Legend™ Program have been a few areas that have enhanced the farm's productivity and longevity.00:00 Introduction to Thiele Dairy00:33 History and Evolution of Thiele Dairy04:25 Current Operations and Family Involvement09:27 Partnership with STgenetics®18:03 Genomic Testing and Genetic Improvements29:39 Crossbreeding Program and Beef Production35:20 Future Goals and Conclusion

From innovative transplant surgery to genome screenings, Dr. Joe Sirven explores the future of healing.

Do you know the best strategies for genomic testing in NSCLC? Credit available for this activity expires: 4/30/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002496?ecd=bdc_podcast_libsyn_mscpedu

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Janice Walshe, Consultant Medical Oncologist at St Vincent's University Hospital, Dublin, Ireland. They explore the economic realities of cancer diagnostics, fertility preservation in patients with breast cancer, and the impact of international collaboration on the future of clinical trials.  Timestamps:    00:00 – Introduction  03:25 – Economic disparities and oncology care in Ireland  07:20 – Neoadjuvant therapy for HER2-positive breast cancer  10:13 – Spotlight on invasive lobular carcinoma  12:36 – Fertility preservation in breast cancer  15:20 – Menopause after cancer  19:09 – The latest clinical trials in Ireland  21:50 – International trials and research projects  23:50 – Walshe's three wishes for healthcare 

In this STtalks, we sit down with Adelyn Allen, STgenetics® Beef Operations Manager and Francine Campagnari, STgenetics® Senior Research and Development Manager, to learn more about STgenetics® Brahman division and the success they have recently experienced. In this discussion we learn about the American Brahman Breeders Association Performance Breeder of the Year award that STgenetics® received along with the role Vision+™ genomic testing will play within breeding strategies and the next generation of Brahman cattle. Tune in for insights into how these advancements are setting new standards in genetic excellence and sustainability.00:00 Welcome and Introductions00:41 STgenetics®' Brahman Division Award03:13 Genetic Offerings and Data Collection04:48 Brahman Spring Production Sale07:37 Vision+™ Genomic Testing09:37 Impact of Genomic Testing14:39 Final Thoughts and Wrap-Up

As we celebrate Easter, STgenetics® recalls its partnership with the Easter Bunny to provide more joy, sustainability and efficiency to the Bunny Business! Tune in as we unfold how STgenetics® tools and technology have helped the Easter Bunny produce higher quality Easter eggs while also reducing environmental impact, a truly egg-celent story!00:00 Introduction to Easter Celebration00:28 The Easter Bunny's Sustainable Business00:55 Genomic Testing for Efficient Egg Production01:10 EcoFeed® Suite and Environmental Benefits01:40 Donor Output Index and Enhanced Egg Production02:16 Conclusion and Easter Wishes

An interesting new study from the Geisinger health system in Pennsylvania examining if genomic screening in a large population increases the identification of disease risk prompted Raise the Line to re-release a previous episode about a textbook designed to help all medical providers understand the clinical applications of genomic testing. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counseling from Elsevier Science Direct dives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases. Mentioned in this episode: Genomics in the Clinic: A Practical Guide If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Join us as we sit down with Full Circle Dairy of Lee, Florida to learn about their remarkable growth through strategic genetic strategies and their innovative herd management. Greg Watts, Eric Diepersloot and Phillip Watts join us to share about their genetic journey as well as their current expansion plans. Full Circle Dairy has utilized STgenetics® Legend™ Program to boost their genetic growth and through a deliberate mating plan have been able to achieve 150 NM$ interval jumps over the past three years. This growth is not only shown within the consistency and quality of their herd but through their production and reproduction milestones as well. With plans to expand from their internal genetics only, Full Circle Dairy has quite the story and goals to share on this STtalks episode!00:00 Introduction to Full Circle Dairy00:40 Meet the Team: Roles and Responsibilities01:46 Current Operations and Growth Plans03:06 Challenges and Adaptations03:34 Partnership with STgenetics®05:37 Transition to Gender Sorted Semen06:38 Nutritional Adjustments for Better Conception Rates11:27 Genomic Testing and the Legend™ Program20:07 Breeding Strategies and Expansion30:32 Future Goals and Reflections34:30 Conclusion and Farewell

We kick off 2025 on Raise the Line by sharing some good news for providers struggling to keep up with the growing number of applications for genomic testing: a new book from Elsevier Science Direct has been designed to arm you with the knowledge you need. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counselingdives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases.Mentioned in this episode: Genomics in the Clinic: A Practical Guide

Dr. Evan Yu presents the new evidence-based guideline on genetic testing for metastatic prostate cancer. He discusses who should receive germline and somatic testing with next-generation sequencing technologies, what samples are preferred for testing, and the therapeutic & prognosistc impacts of genetic testing. Dr. Yu emphasizes the need for awareness and refers to areas of active investigation and future research to improve personalized therapies for patients with metastatic prostate cancer.  Read the full guideline, “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline” at www.asco.org/genitourinary-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02608 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Evan Yu from the University of Washington and Fred Hutchinson Cancer Center, lead author on “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline”. Thank you for being here today, Dr. Yu. Dr. Evan Yu: Thanks for having me on. Brittany Harvey: Great. Then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the entire guideline, including Dr. Yu, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, Dr. Yu, to start us off on the content of this guideline, could you first provide an overview of both the purpose and scope of this guideline? Dr. Evan Yu: Yeah, absolutely. So I think the one key thing to recognize is that prostate cancer is the highest incidence of all cancers in males. Additionally, it's the second highest cause of mortality in males, and that's about 35,000 deaths in 2024. So with that being said and done, it's a disease where we need to do better. And part of that is recognizing that we now have many targeted therapies, precision medicine type of therapies, but unlike a lot of other cancers out there, prostate cancer patients are not always getting sequencing, next generation DNA sequencing, let's say, to identify both inherited and also spontaneously develop what we call somatic mutations in their tumor. And I suspect that's partially because other cancers like breast cancer, we're so used to- in the first line, you present the patient, you throw out their estrogen receptor status, progesterone receptor status, HER2, ER/PR HER2; in lung cancer it's EGFR, ALK, ROS1, etc. In things like prostate cancer, things like BRCA2 have major important patient treatment implications and potentially family counseling and downstream cascade testing implications. But it hasn't made their way into that first-line presentation yet. And for that reason, there are some studies out there that show that testing in the community may be as low as 15% of patients with metastatic prostate cancer. We want to bring awareness to that and hopefully increase testing down the road so that we can better help our patients with metastatic prostate cancer. Brittany Harvey: Absolutely. It's important to get these targeted therapies to the patients who can benefit most. Using that context, I'd like to next review the key recommendations of this guideline across the six clinical questions that the panel addressed. So, starting with: Who should receive germline testing with next generation sequencing technologies? Dr. Evan Yu: Yeah. We think that it's common enough that everyone with metastatic prostate cancer should receive germline genetic testing. And the reason for that is there have been studies that have looked at this and have shown that 12% of men with metastatic prostate cancer have some sort of inherited germline mutation in a gene, mostly DNA repair genes. But 12% have something that is inherited and that loved ones, first degree relatives, siblings, offspring might have also inherited. Now, most of these are in the DNA repair genes, but that being said and done, there's not only treatment implications for the patient, where there are newer drugs that that patient could get treated with, but other loved ones that might have inherited these gene mutations, that these things can cause other cancers as well - not just prostate cancer, but breast cancer, endometrial cancer, ovarian cancer, pancreatic cancer. So, it's very important to test, with as high of an incidence as 12%, to test, and if you identify it in a patient, it's our job to talk to the patient about it and talk to them about the pros and cons of family counseling and talking to their loved ones and potentially having their loved ones get tested. Because if they test positive, then their doctors may want to know and may screen them very, very aggressively and differently for a whole host of other cancers. And the whole idea is you find the cancer very early and cure the patients before the cancer really takes hold and has the ability to spread so we can save a lot of lives down the road. Brittany Harvey: Absolutely. This germline testing is important not just for the patient, but has wider implications for their families as well, as you mentioned. So then, beyond those recommendations for germline testing, which patients should receive somatic testing with next-generation sequencing technologies? Dr. Evan Yu: So let's talk a little bit about somatic testing. So germline again, as we know, is inherited. The patient inherited it in every single cell in their body, then it becomes very easy, many of these are cancer predispositions for them to lose the other allele and then to have biallelic loss and then develop the cancer. Now, somatic just means it spontaneously occurred. Certainly, it's not going to occur in every cell in the body, but you can get one hit, lose one allele and then lose the other allele. And if that gene is truly carcinogenic and leading to that cancer, then that can have implications potentially for treatment as well. So we recommend that all patients with metastatic prostate cancer also undergo somatic next-generation sequencing testing. We recognize that at this point in time it's only those with metastatic castration-resistant prostate cancer or hormone-resistant prostate cancer, which is a later disease state where there are drugs that may target those mutations, for instance, like PARP inhibitors, but that early identification for a patient population that's fit and that can benefit from these therapies makes sense so that you know it's in place already and you have your treatments outlined and mapped out for the future. So we recommend it for everybody - somatic testing also for everyone with metastatic prostate cancer. Brittany Harvey: Understood. And then when patients are receiving that somatic testing, what is recommended for somatic testing? Primary tumor archival tissue? Fresh metastatic biopsy tissue? Or circulating tumor DNA testing? Dr. Evan Yu: We recommend that in the initial setting when you're first diagnosed, that archival tissue samples are fine and preferred. But circulating tumor DNA is good when there's no accessible archival tissue, or if the archival tissue, let's say, is very old and it's been sitting around for a long time, or you can't get it anymore because it's many years back when maybe a patient had a prostate needle biopsy. So if it's not accessible, then we recommend ctDNA. We believe that is preferred and also that ctDNA is recommended in a situation where you can't easily biopsy a metastatic site. Sometimes it's just not in a safe area to go after. Sometimes it's just a small lesion. So in general, we recommend tissue when available, and when we think that the tissue sample will yield clean results, if not, then we recommend doing ctDNA at that point in time. Brittany Harvey: So you have described who should get germline and somatic genomic testing. But what are the therapeutic impacts of this germline or somatic testing for single gene genetic variants? Dr. Evan Yu: We pulled this panel together and we met like every single month for like 12 months straight, and part of it was to review the literature. And as part of this literature review, we were able to pull a whole bunch of different trials. I think there was like 1713 papers we identified in the literature search. Eventually, we narrowed it down because with ASCO, we want to present the data with the highest level evidence, level 1 evidence, randomized controlled prospective data. And after reviewing 1713 papers, we narrowed it down to 14 papers. With those 14 papers, if you look at it, there are a lot of things that we think may have implications for treatment or prognosis, but we didn't feel was the highest level of evidence that we could support. So the things that have the highest level of evidence that we can support are certain DNA repair gene alterations, especially BRCA2, and treatment with PARP inhibitors because there are many PARP inhibitor prospective trials that show progression-free survival benefit and even overall survival benefit. And so that's the type of study that achieved the level of evidence that we could include. So I would say BRCA1 and BRCA2 highest level of evidence and PARP inhibitor use also is included in that. Brittany Harvey: Understood. I appreciate you reviewing those therapeutic options. So then, the last clinical question, which you just touched on briefly, but what are the prognostic impacts of germline and/or somatic testing? Dr. Evan Yu: Whenever you do testing, especially if you use panel testing, you find a lot of information. There's a lot of different mutations and some of which are VUSs (variants of unknown significance) where we don't quite know what it means yet, but we can track that, especially if it's germline. But with somatic, we find lots of things that have implications, but maybe just not treatment implications. A perfect example is p53. p53 is one of the most common tumor suppressor gene mutations on all cancers, but in prostate cancer they can occur and they can usually occur late, although there can even be germline inherited p53 alterations. There's no treatment that targets p53 right now, but we know that if you have a p53 mutation that those patients may have more aggressive disease and that prognostic information is important to give to the patient. And I think it's important for future clinical trial design and direction. So we do not recommend making treatment recommendations or changes based on these prognostic only biomarkers at this point in time. But we do recommend that, based on this, we can design intensification trials for those patients who have these poor risk biomarkers and de-intensification trials for patients who may have a good risk biomarker. So for instance, SPOP is a gene where we think these patients may have better outcomes, they might respond better to certain hormonal therapies like abiraterone. I say might because the level of evidence isn't quite there. But what I would say is that these prognostic only biomarkers, we just don't think they cut the mustard yet to be able to make treatment decisions. But we do think that they can drive counseling for the patient and potential selection and trial design for the future to say, “Okay. This is a patient population that has a more aggressive cancer. We need to be more aggressive in treating these patients.” “This patient population might have a less aggressive cancer. Maybe we can de-intensify and say side effects and quality of life may be better for the patients.” Brittany Harvey: Definitely. It's important for thinking through how to personalize care for these patients. So then you've talked about this a little bit in talking through the recommendations, but could you expand on what is the importance of this guideline and how it will impact both clinicians and patients with metastatic prostate cancer? Dr. Evan Yu: Yeah, I think the number one thing is awareness. I think the data's out there and people that are in my field, they know this. But by evidence of the fact that it's not first-line presentation lingo that everyone's talking about things like BRCA status, it means it hasn't necessarily disseminated all the way through. So it's increasing awareness of the fact that both germline and somatic alterations can occur and that these may have impacts on the patient for their treatment and their prognosis, and basically to increase testing for the future. I really think that in the future, there'll be other reasons that we may want to serially even retest and we may find that there may be mutations that develop as mechanisms of resistance that might guide therapy down the road. So we need to get people to start doing this for everyone with metastatic prostate cancer, because someday we might be doing it not just once, but over and over again. Brittany Harvey. Absolutely. We hope this guideline reaches a wide audience and that these recommendations can be put into practice. Finally, you've talked about how not all the data in the field has yet risen to the level of evidence that made it into the guidelines. So what are the outstanding questions in future research areas for both germline and somatic genomic testing for metastatic prostate cancer? Dr. Evan Yu: It was in our discussion, but it clearly- it's not common enough for there to be randomized prospective trials that would reach that level of evidence to make it in this guideline recommendation. But we all know that for any solid tumor, you can get mismatched repair deficiency, microsatellite instability leading to hypermutation or high tumor mutational burden. And that happens in maybe 3 to 5% of patients with metastatic prostate cancer as well. There is evidence and data that these patients can potentially benefit from immunotherapies like pembrolizumab. But again, it's just not common enough for there to be those randomized prospective controlled trials out there. But we mention it because we know it's FDA-approved across all the tumor types, so we felt like we have to mention it because that's something that has treatment implications for the patient. But also, I alluded to this earlier, I think an area of active investigation is the tried and true number one driver of prostate cancer, which is androgen receptor. Testosterone binds to androgen receptors, stimulates it. That's how androgen deprivation therapy works. That's how abiraterone and the amides like enzalutamide, apalutamide, darolutamide, that's how they all work. But even beyond that, we're starting to identify that maybe 15%, 20% of patients with metastatic castration resistant prostate cancer have androgen receptor mutations. And there are newer classes of therapies like androgen receptor degraders like CYP11A1 antagonist that lead to complete adrenal annihilation of other steroid hormones that might promiscuously stimulate these androgen receptor mutants. These things develop as mechanisms of resistance, and in the future, we might want to serially test- and that's an active area of investigation in the future, to say you've been treated, let's say, with androgen deprivation therapy and abiraterone for years. There are certain mutations that might develop as a resistance mechanism. We might need to serially test somebody because you didn't have that mutation earlier on, but later in the disease course you might. And then there might be a new drug X out there that we would want to use. Again, we need the data, we need the randomized prospective controlled trials, but they're happening out there. And somewhere down the road we may rewrite this guideline and have a lot more recommendations to add to it. Brittany Harvey: Yes, we'll look forward to more research in this field to better provide targeted therapies for patients with metastatic prostate cancer across the treatment paradigm. And we'll look forward to report outs from those trials that you mentioned. So I want to thank you so much for your work to develop this guideline and thank you for your time today, Dr. Yu. Dr. Evan Yu: Thank you so much. It's wonderful to be here today. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Join us as we learn more about the 2024 MILK Business Leader in Technology Award winner, GenoSource! We sit down with Tim Rauen, GenoSource's CEO and Part-Owner to learn about the farm and the technologies he believes are pushing GenoSource forward and helping them achieve their goals! Technology is immersed within all that GenoSource does and Tim goes into details on what is used within GenoSource's infrastructure as well as on the genetic side of their business. 00:00 Introduction and Guest Welcome 00:39 Overview of GenoSource 01:19 Production and Facilities at GenoSource 02:11 Unique Technologies at GenoSource 02:55 Early Adoption of Genomic Testing and IVF 04:14 STgenetics®' Technologies and Infrastructure 07:24 IVF Program Scale and Goals 09:14 Achievements and Future Plans 12:24 Conclusion and Final Thoughts

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

In this episode, Dr. Bravo and Dr. Rogu speak with Dr. Molly O'Shea, a pediatrician and owner of a holistic family practice in Michigan. They discuss the emerging field of personalized medicine in Michigan and Dr. O'Shea's journey into pediatrics. Dr. O'Shea shares her experiences, detailing her innovative practice model, including home visits and a holistic approach. She also delves into the significance of genetic screening in early childhood and her work with rare diseases. The conversation covers pediatric care's challenges and potential future, touching on the importance of mental health, the microbiome, and the evolving role of primary care in pediatrics.This episode is sponsored by our friends at Freed.ai. Without their generous contribution, the show would not be possible. Dr. Rougu uses this product daily, and as he says, "It has changed my life. I don't work anymore."   Please visit their website and support our sponsors. 00:00 Introduction and Setting the Scene00:09 Meet Dr. Molly O'Shea01:02 Dr. Molly's Journey to Pediatrics04:42 Family Influence and Childhood Challenges06:26 Resilience and Overcoming Adversity13:20 Innovative Pediatric Practice24:48 Personalized Medicine and Rare Diseases34:00 Advocacy and Future Projects37:29 The Illusion of Deleting Social Media Data38:10 Understanding Genetic Conditions: Monogenic vs Polygenic44:25 Penetrance and Its Role in Genetic Conditions51:47 Challenges in Pediatric Genetic Screening56:06 Future of Pediatrics: Personalized Medicine and Microbiome01:00:20 The Financial Struggles in Pediatric Care01:06:57 The Role of Extenders in Pediatric Practice01:12:49 Concluding Thoughts and Future MeetingsSupport the show

When it comes to management changes, the path from asking “Does it make sense?” to achieving more success is rarely clear. But when a dairy navigates that journey, the rewards can be plentiful — and can lead to additional opportunities to refine and improve productivity. Beth Dahl joins us from Mountain View Dairy in Delta, Utah. Beth has firsthand experience using genomic testing with CLARIFIDE® Plus, having stood where many of you are today, asking herself, “Does this make sense?” Ultimately, Beth, alongside Mountain View Dairy, jumped into the implementation and application of genomic testing with two feet and hasn't looked back.

We must remember that the people working long hours to achieve a dairy's production goals are still just people. And they invest more than just labor into an operation's success. Beth Dahl of Mountain View Dairy in Delta, Utah, has a lot to say about how her team finally solved a yearslong problem with bloating in calves thanks to some help from genomic testing with CLARIFIDE® Plus. 

Tumor profiling or genomic testing can give us information about the genes in a person's cancer cells and can help guide doctors to the best possible treatment plan by predicting the risk of recurrence, or when breast cancer returns after initial treatment. If a low risk of recurrence is shown, people with breast cancer and their doctors can choose to pursue a less aggressive treatment plan with confidence. Here today to empower us with information about the power of genomics and to give further insight into how it can positively affect treatment decisions is Medical Oncologist, specializing in Breast Cancer and Cancer Genomics, and Chief Medical Officer at Agendia, Dr. William Audeh.

Join us for an enlightening journey as we sit down with Stewart Staudinger, who shares his remarkable transition from an aeronautical engineer and Royal Air Force pilot to a full-time bison rancher in central Alberta. Stewart recounts his early years on a purebred Simmental cattle ranch and his eventual return to the family ranch, inspired by his father's shift from cattle to bison. Listen in as Stewart provides a vivid picture of the unique management aspects of bison, their wild nature, and the fascinating dynamics of herd behavior.We also explore the intricacies of bison genetics and breeding strategies, highlighting the differences between plains and wood bison subspecies and the advancements in genomic testing. Stewart discusses the practical aspects of handling and weaning calves, sharing the learning curve new ranchers face. Our conversation emphasizes the importance of these genetic discoveries for herd registry management and classification, providing invaluable insights for those interested in bison ranching.In the latter part of our discussion, we shift focus to the operational aspects of running a diverse meat business and the challenges of grazing management. Stewart shares his experiences with marketing strategies, feeding regimens, and the significant infrastructure improvements he's implemented to support sustainable grazing practices. From innovative fencing techniques using sucker rod to enhancing soil health through regenerative agriculture, Stewart's journey offers a wealth of knowledge for anyone interested in sustainable and profitable ranching. Tune in to gain a comprehensive understanding of the multifaceted world of regenerative bison ranching.Links Mentioned in the Episode:MFL Bison Ranch Visit our Sponsors:Noble Research InstituteKencove Farm Fence

Pharmacogenomics plays a critical role in personalised medicine, as some adverse drug reactions are genetically determined. Adverse drugs reactions (ADRs) account for 6.5% of hospital admissions in the UK, and the application of pharmacogenomics to look at an individuals response to drugs can significantly enhance patient outcomes and safety. In this episode, our guests discuss how genomic testing can identify patients who will respond to medications and those who may have adverse reactions. We hear more about Genomics England's collaboration with the Medicines and Healthcare products Regulatory Agency in the Yellow Card Biobank and our guests discuss the challenges of implementing pharmacogenomics into the healthcare system. Our host Vivienne Parry, Head of Public Engagement at Genomics England, is joined by Anita Hanson, Research Matron and the Lead Research Nurse for clinical pharmacology at Liverpool University Hospitals NHS Foundation Trust, and Professor Bill Newman, Professor of translational genomic medicine at the Manchester Center for Genomic Medicine, and Professor Matt Brown, Chief Scientific Officer at Genomics England.   "I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record."   To learn more about Jane's lived experience with Stevens-Johnson syndrome, visit The Academy of Medical Sciences' (AMS) YouTube channel. The story, co-produced by Areeba Hanif from AMS, provides an in-depth look at Jane's journey. You can watch the video via this link: https://www.youtube.com/watch?v=v4KJtDZJyaA  Want to learn more about personalised medicine? Listen to our Genomics 101 episode where Professor Matt Brown explains what it is in less than 5 minutes: https://www.genomicsengland.co.uk/podcasts/genomics-101-what-is-personalised-medicine  You can read the transcript below or download it here: https://www.genomicsengland.co.uk/assets/documents/Podcast-transcripts/Can-genomic-testing-prevent-adverse-drug-reactions.docx   Vivienne: Hello and welcome to Behind the Genes.  Bill: What we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So, a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing.  Vivienne: My name's Vivienne Parry and I'm head of public engagement at Genomics England, and today we'll be discussing the critical role of pharmacogenomics in personalised medicine, highlighting its impact on how well medicines work, their safety, and on patient care. I'm joined today by Professor Bill Newman, professor of translational genomic medicine at the Manchester Centre for Genomic Medicine, Anita Hanson, research matron, a fabulous title, and lead research nurse for clinical pharmacology at the Liverpool University Hospital's NHS Foundation Trust, and Professor Matt Brown, chief scientific officer for Genomics England. And just remember, if you enjoy today's episode, we'd love your support, so please like, share and rate us on wherever you listen to your podcasts.  So, first question to you, Bill, what is pharmacogenomics?  Bill: Thanks Viv. I think there are lots of different definitions, but how I think of pharmacogenetics is by using genetic information to inform how we prescribe drugs, so that they can be safer and more effective. And we're talking about genetic changes that are passed down through families, so these are changes that are found in lots of individuals. We all carry changes in our genes that are important in how we transform and metabolise medicines, and how our bodies respond to them.  Vivienne: Now, you said pharmacogenetics. Is it one of those medicine things like tomato, tomato, or is there a real difference between pharmacogenetics and pharmacogenomics?  Bill: So, people, as you can imagine, do get quite irate about this sort of thing, and there are lots of people that would contest that there is a really big important difference. I suppose that pharmacogenetics is more when you're looking at single changes in a relatively small number of genes, whereas pharmacogenomics is a broader definition, which can involve looking at the whole genome, lots of genes, and also whether those genes are switched on or switched off, so the expression levels of those genes as well would encompass pharmacogenomics. But ultimately it's using genetic information to make drug prescription safer and more effective.  Vivienne: So, we're going to call it pharmacogenomics and we're talking about everything, that's it, we'll go for it. So Matt, just explain if you would the link between pharmacogenomics and personalised medicine. And I know that you've done a big Genomics 101 episode about personalised medicine, but just very briefly, what's the link between the two?  Matt: So, personalised medicine's about using the right dose of the right drug for the right individual. And so pharmacogenomics helps you with not only ensuring that you give a medication which doesn't cause problems for the person who receives it, so an adverse drug reaction, but also that they're actually getting the right dose. Of course, people's ability to metabolise, activate and respond to drugs genetically is often genetically determined, and so sometimes you need to adjust the dose up or down according to a person's genetic background.  Vivienne: Now, one of the things that we've become very aware of is adverse drug reactions, and I think they account for something like six and a half percent of all hospital admissions in the UK, so it's absolutely huge. Is that genetically determined adverse drug reactions?  Matt: So, the answer to that is we believe so. There's quite a bit of data to show that you can reduce the risk of people needing a hospital admission by screening genetic markers, and a lot of the very severe reactions that lead to people being admitted to hospital are very strongly genetically determined. So for example, there are HLA types that affect the risk of adverse drug reactions to commonly used medications for gout, for epilepsy, some HIV medications and so on, where in many health services around the world, including in England, there are already tests available to help prevent those leading to severe reactions. It's likely though that actually the tests we have available only represent a small fraction of the total preventable adverse drug reactions were we to have a formal pre-emptive pharmacogenomics screening programme.  Vivienne: Now, I should say that not all adverse drug reactions are genetic in origin. I mean, I remember a rather nasty incident on the night when I got my exam results for my finals, and I'd actually had a big bee sting and I'd been prescribed antihistamines, and I went out and I drank rather a lot to celebrate, and oh my goodness me, I was rather ill [laughter]. So, you know, not all adverse drug reactions are genetic in origin. There are other things that interact as well, just to make that clear to people.  Matt: Yes, I think that's more an interaction than an adverse drug reaction. In fact frankly, the most common adverse drug reaction in hospitals is probably through excess amounts of water, and that's not medically determined, that's the prescription.  Vivienne: Let me now come to Anita. So, you talk to patients all the time about pharmacogenomics in your role. You've been very much involved in patient and public involvement groups at the Wolfson Centre for Personalised Medicine in Liverpool. What do patients think about pharmacogenomics? Is it something they welcome?  Anita: I think they do welcome pharmacogenomics, especially so with some of the patients who've experienced some of the more serious, life threatening reactions. And so one of our patients has been doing some work with the Academy of Medical Sciences, and she presented to the Sir Colin Dollery lecture in 2022, and she shared her story of having an adverse drug reaction and the importance of pharmacogenomics, and the impact that pharmacogenomics can have on patient care.  Vivienne: Now, I think that was Stevens-Johnson syndrome. We're going to hear in a moment from somebody who did experience Stevens-Johnson's, but just tell us briefly what that is.  Anita: Stevens-Johnson syndrome is a potentially life threatening reaction that can be caused by a viral infection, but is more commonly caused by a medicine. There are certain groups of medicines that can cause this reaction, such as antibiotics or anticonvulsants, nonsteroidal anti-inflammatories, and also a drug called allopurinol, which is used to treat gout. Patients have really serious side effects to this condition, and they're often left with long-term health complications. The morbidity and mortality is considerable as well, and patients often spend a lot of time in hospital and take a long time to recover.   Vivienne: And let's now hear from Jane Burns for someone with lived experience of that Stevens-Johnson syndrome. When Jane Burns was 19, the medicine she took for her epilepsy was changed.  Jane: I remember waking up and feeling really hot, and I was hallucinating, so I was taken to the Royal Liverpool Hospital emergency department by my parents. When I reached A&E, I had a temperature of 40 degrees Celsius. I was given Piriton and paracetamol, and the dermatologist was contacted. My mum had taken my medication to hospital and explained the changeover process with my epilepsy medication. A decision was made to discontinue the Tegretol and I was kept in for observation. Quite rapidly, the rash was changing. Blisters were forming all over my body, my mouth was sore and my jaw ached. My temperature remained very high. It was at this point that Stevens-Johnson syndrome, or SJS, was diagnosed.  Over the next few days, my condition deteriorated rapidly. The rash became deeper in colour. Some of the blisters had burst, but some got larger. I developed ulcers on my mouth and it was extremely painful. I started to lose my hair and my fingernails. As I had now lost 65 percent of my skin, a diagnosis of toxic epidermal necrolysis, or TEN, was made. Survivors of SJS TEN often suffer with long-term visible physical complications, but it is important to also be aware of the psychological effects, with some patients experiencing post-traumatic stress disorder. It's only as I get older that I realise how extremely lucky I am to have survived. Due to medical and nursing expertise, and the research being conducted at the time, my SJS was diagnosed quickly and the medication stopped. This undoubtedly saved my life.  Vivienne: Now, you've been looking at the development of a passport in collaborating with the AMS and the MHRA. Tell me a bit more about that.  Anita: Yes, we set up a patient group at the Wolfson Centre for Personalised Medicine approximately 12 years ago, and Professor Sir Munir Pirmohamed and I, we wanted to explore a little bit more about what was important to patients, really to complement all the scientific and clinical research activity within pharmacogenomics. And patients recognised that, alongside the pharmacogenomic testing, they recognised healthcare professionals didn't really have an awareness of such serious reactions like Stevens-Johnson syndrome, and so they said they would benefit from having a My SJS Passport, which is a booklet that can summarise all of the important information about their care post-discharge, and this can then be used to coordinate and manage their long-term healthcare problems post-discharge and beyond. And so this was designed by survivors for survivors, and it was then evaluated as part of my PhD, and the findings from the work suggest that the passport is like the patient's voice, and it really does kind of validate their diagnosis and raises awareness of SJS amongst healthcare professionals. So, really excellent findings from the research, and the patients think it's a wonderful benefit to them.  Vivienne: So, it's a bit like a kind of paper version of the bracelet that you sometimes see people wearing that are on steroids, for instance.  Anita: It is like that, and it's wonderful because it's a handheld source of valuable information that they can share with healthcare professionals. And this is particularly important if they're admitted in an emergency and they can't speak for themselves. And so the passport has all that valuable information, so that patients aren't prescribed that drug again, so it prevents them experiencing a serious adverse drug reaction again.   Vivienne: So, Stevens-Johnson, Bill, is a really scary side effect, but what about the day to day benefits of pharmacogenomics for patients?  Bill: So, what we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing.   And it's not just in terms of side effects. It's in terms of the effectiveness of the medicine. Because if a person is prescribed a medicine that doesn't or isn't going to work for them then it can take them longer to recover, to get onto the right medicine. That can have all sorts of detrimental effects. And so when we're thinking about introducing pharmacogenetics more broadly rather than just on a single drug or a single gene basis, we're thinking about that for common drugs like antidepressants, painkillers, statins, the drugs that GPs are often prescribing on a regular basis to a whole range of patients.  Vivienne: So, to go back to you, Anita, we're really talking about dose here, aren't we, whether you need twice the dose or half the dose depending on how quickly your body metabolises that particular medicine. How do patients view that?  Anita: Well, the patient in question who presented for the Academy of Medical Sciences, I mean, her take on this was, she thinks pharmacogenetics is wonderful because it will allow doctors and nurses to then prescribe the right drug, but also to adapt the dose accordingly to make sure that they get the best outcome, which provides the maximum benefit while also minimising any potential harm. And so from her perspective, that was one of the real benefits of pharmacogenomics. But she also highlighted about the benefits for future generations, the fear of her son taking the same medicine and experiencing the same reaction. And so I think her concerns were, if we have pharmacogenetic testing for a panel of medicines, as Bill mentioned then, then perhaps this would be fantastic for our children as they grow up, and we can identify and predict and prevent these type of reactions happening to future generations.  Vivienne: And some of these drugs, Bill, are really very common indeed, something like codeine. Just tell us about codeine, ‘cos it's something – whenever I tell this to friends [laughter], they're always completely entranced by the idea that some people don't need nearly as much codeine as others.  Bill: Yeah, so codeine is a drug that's very commonly used as a painkiller. To have its real effect, it needs to be converted in the body to a different drug called morphine, and that is done by an enzyme which is made by a gene called CYP2D6. And we all carry changes in CYP2D6, and the frequency of those variants, whether they make the gene work too much or whether they make it work too little, they vary enormously across the world, so that if you go to parts of Africa, about 30 percent of the population will make more of the CYP2D6, and so they will convert the codeine much more quickly, whereas if you go to the UK, maybe up to ten percent of the white population in the UK just won't be converting codeine to morphine at all, so they won't get any benefit from the drug. So at both ends, you have some people that don't respond and some people that respond a little bit too much so that they need either an alternative drug or they need a different dose.  Vivienne: So, all those people who say, you know, “My headache hasn't been touched by this painkiller,” and we say, “What a wimp you're being,” actually, it's to do with genetics.  Bill: Yeah, absolutely. There's a biological reason why people don't – not for everybody, but for a significant number of people, that's absolutely right, and we can be far more tailored in how we prescribe medication, and get people onto painkillers that work for them much more quickly.  Vivienne: And that's so interesting that it varies by where you come from in the world, because that means we need to give particular attention – and I'm thinking, Anita, to working with patients from different community groups, to make sure that they understand the need for pharmacogenomics.  Anita: I think that's really important, Vivienne, and I think we are now having discussions with the likes of Canada SJS awareness group, and also people have been in touch with me from South Africa because people have requested the passport now to be used in different countries, because they think it's a wonderful tool, and it's about raising awareness of pharmacogenomics and the potential benefits of that, and being able to share the tools that we've got to help patients once they've experienced a serious reaction.  Vivienne: So, pharmacogenomics clearly is important in the prevention of adverse drug reactions, better and more accurate prescribing, reduced medicines wastage. Does this mean that it's also going to save money, Bill, for the NHS?  Bill: Potentially. It should do if it's applied properly, but there's lots of work to make sure that not only are we using the right evidence and using the right types of tests in the laboratory, but we're getting the information to prescribers, so to GPs, to pharmacists, to hospital doctors, in a way that is understandable and meaningful, such that they can then act upon that information. So, the money will only be saved and then can be reused for healthcare if the whole process and the whole pathway works, and that information is used effectively.  Vivienne: So, a lot of research to make sure that all of that is in place, and to demonstrate the potential cost savings.  Bill: Yes. I mean, there are very nice studies that have been done already in parts of the world that have shown that the savings that could be accrued for applying pharmacogenetics across common conditions like depression, like in patients to prevent secondary types of strokes, are enormous. They run into hundreds of millions of pounds or dollars. But there is an initial investment that is required to make sure that we have the testing in place, that we have the digital pathways to move the information in place, and that there's the education and training, so that health professionals know how to use the information. But the potential is absolutely enormous.  Vivienne: Matt, can I turn now to the yellow card. So, people will be very familiar with the yellow card system. So, if you have an adverse reaction, you can send a yellow card in – I mean, literally, it is a yellow card [laughter]. It does exactly what it says on the tin. You send a yellow card to the MHRA, and they note if there's been an adverse effect of a particular medicine. But Genomics England is teaming up with the MHRA to do something more with yellow cards, and we're also doing this with the Yellow Card Biobank. Tell us a bit more.  Matt: So, yellow card's a great scheme that was set up decades ago, initially starting off, as you said, with literally yellow cards, but now actually most submissions actually come online. And it's important to note that submissions can come not just from healthcare providers, but majority of submissions actually come from patients themselves, and that people should feel free, if they feel they've had an adverse drug reaction, to report that themselves rather than necessarily depending on a medical practitioner or the healthcare provider to create that report. So, Genomics England is partnering with the MHRA in building what's called the Yellow Card Biobank, the goal of which is to identify genetic markers for adverse drug reactions earlier than has occurred in the past, so that we can then introduce genetic tests to prevent these adverse drug reactions much sooner than has occurred previously.   So, what we're doing is basically at the moment we're doing a pilot, but the ultimate plan is that in future, patients who report a serious adverse drug reaction through the Yellow Card Biobank will be asked to provide a sample, a blood sample, that we then screen. We do a whole genome sequence on it, and then combine these with patients who've had like adverse drug reactions and identify genetic markers for that adverse drug reaction medication earlier, that can then be introduced into clinical practice earlier. And this should reduce by decades the amount of time between when adverse drug reactions first start occurring with medications and us then being able to translate that into a preventative mechanism.  Vivienne: And will that scheme discover, do you think, new interactions that you didn't know about before? Or do you expect it to turn up what you already know about?  Matt: No, I really think there's a lot of discovery that is yet to happen here. In particular, even for drugs that we know cause adverse drug reactions, mostly they've only been studied in people of European ancestry and often in East Asian ancestry, but in many other ancestries that are really important in the global population and in the UK population, like African ancestry and South Asian ancestries, we have very little data. And even within Africa, which is an area which is genetically diverse as the rest of the world put together, we really don't know what different ethnicities within Africa, actually what their genetic background is with regard to adverse drug reactions.  The other thing I'd say is that there are a lot of new medications which have simply not been studied well enough. And lastly, that at the moment people are focused on adverse drug reactions being due to single genetic variants, when we know from the model of most human diseases that most human diseases are actually caused by combinations of genetic variants interacting with one another, so-called common disease type genetics, and that probably is similarly important with regard to pharmacogenomics as it is to overall human diseases. That is, it's far more common that these are actually due to common variants interacting with one another rather than the rare variants that we've been studying to date.  Vivienne: So, it's a kind of cocktail effect, if you like. You know, you need lots of genes working together and that will produce a reaction that you may not have expected if you'd looked at a single gene alone.  Matt: That's absolutely correct, and there's an increasing amount of evidence to show that that is the case with medications, but it's really very early days for research in that field. And the Yellow Card Biobank will be one of many approaches that will discover these genetic variants in years to come.  Vivienne: Now, Matt's a research scientist. Bill, you're on the frontline in the NHS. How quickly can this sort of finding be translated into care for people in the NHS?  Bill: So, really quickly is the simple answer to that, Viv. If we look at examples from a number of years ago, there's a drug called azathioprine that Matt has used lots in some of his patients. In rheumatology, it's used for patients with inflammatory bowel disease. And the first studies that showed that there was a gene that was relevant to having bad reactions to that drug came out in the 1980s, but it wasn't until well into this century, so probably 30-plus years later that we were routinely using that test in clinical medicine. So, there was an enormous lot of hesitancy about adopting that type of testing, and a bit of uncertainty. If you move forward to work that our colleague Munir Pirmohamed in Liverpool has done with colleagues in Australia like Simon Mallal around HIV medicine, there was this discovery that a drug called abacavir, that if you carried a particular genetic change, that you had a much higher risk of having a really severe reaction to that. The adoption from the initial discovery to routine, worldwide testing happened within four years.   So, already we've seen a significant change in the appetite to move quickly to adopt this type of testing, and I see certainly within the NHS and within other health systems around the world, a real desire to adopt pharmacogenetics into routine clinical practice quickly and at scale, but also as part of a broader package of care, which doesn't just solely focus on genetics, but thinks about all the other parts that are important in how we respond to medication. So, making sure we're not on unusual combinations of drugs, or that we're taking our medicine at the right time and with food or not with food, and all of those other things that are really important. And if you link that to the pharmacogenetics, we're going to have a much safer, more effective medicines world.  Vivienne: I think one of the joys of working at Genomics England is that you see some of this work really going into clinical practice very fast indeed. And I should say actually that the Wolfson Centre for Personalised Medicine, the PPI group that Anita looks after so well, they've been very important in recruiting people to Yellow Card Biobank. And if anyone's listening to this, Matt, and wants to be part of this, how do they get involved? Or is it simply through the yellow card?  Matt: So at the moment, the Yellow Card Biobank is focusing on alopurinol.   Vivienne: So, that's a medicine you take for gout.  Matt: Which I use a lot in my rheumatology clinical practice. And direct acting oral anticoagulants, DOACs, which are used for vascular disease therapies and haemorrhage as a result of that. So, the contact details are available through the MHRA website, but I think more importantly, it's just that people be aware of the yellow card system itself, and that if they do experience adverse drug reactions, that they do actually complete a report form, ‘cos I think still actually a lot of adverse drug reactions go unreported.  Vivienne: I'm forgetting of course that we see Matt all the time in the Genomics England office and we don't think that he has any other home [laughter] than Genomics England, but of course he still sees some patients in rheumatology clinic. So, I want to now look to the future. I mean, I'm, as you both know, a huge enthusiast for pharmacogenomics, ‘cos it's the thing that actually, when you talk to patients or just the general public, they just get it straight away. They can't think why, if you knew about pharmacogenomics, why you wouldn't want to do it. But it's not necessarily an easy thing to do. How can we move in the future, Bill, to a more proactive approach for pharmacogenomics testing? Where would we start?  Bill: Yes, so I think we've built up really good confidence that pharmacogenetics is a good thing to be doing. Currently, we're doing that predominantly at the point when a patient needs a particular medicine. That's the time that you would think about doing a genetic test. And previously, that genetic test would only be relevant for that specific drug. I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record. That's what we'd call pre-emptive pharmacogenetic testing, and I think that's the golden land that we want to reach.  Vivienne: So for instance, I might have it on my NHS app, and when I go to a doctor and they prescribe something, I show my app to the GP, or something pops up on the GP's screen, or maybe it's something that pops up on the pharmacist's screen.  Bill: I think that's right. I think that's what we're looking to get to that point. We know that colleagues in the Netherlands have made some great progress at developing pathways around that. There's a lot of public support for that. And pharmacists are very engaged in that. In the UK, the pharmacists, over the last few years, have really taken a very active role to really push forward this area of medicine, and this should be seen as something that is relevant to all people, and all health professionals should be engaged with it.  Vivienne: And on a scale of one to ten, how difficult is it going to be to implement in the NHS?  Bill: So, that's a difficult question. I think the first thing is identifying what the challenges are. So I have not given you a number, I've turned into a politician, not answered the question. So, I think what has happened over the last few years, and some of our work within the NHS Network of Excellence in pharmacogenetics and some of the other programmes of work that have been going on, is a really good, honest look at what it is we need to do to try to achieve pharmacogenetics implementation and routine use. I don't think the challenge is going to be predominantly in the laboratory. I think we've got phenomenal laboratories. I think we've got great people doing great genetic testing. I think the biggest challenges are going to be about how you present the data, and that data is accessible. And then ensuring that health professionals really feel that this is information that isn't getting in the way of their clinical practice, but really making a difference and enhancing it, and of benefit both to the healthcare system but more importantly to the patients.  Vivienne: Now, when I hear you both talk, my mind turns to drug discovery and research, and Matt, I'm quite sure that that's right at the top of your mind. Tell us how pharmacogenomics can help in drug discovery and research.  Matt: So, pharmacogenomics, I think actually just genetic profiling of diseases in itself just to start off with is actually a really good way of identifying new potential therapeutic targets, and also from derisking drug development programmes by highlighting likely adverse drug reactions of medications that are being considered for therapeutic trials, or targets that are being considered for therapeutic development. Pharmacogenomics beyond that is actually largely about – well, it enables drug development programmes by enabling you to target people who are more likely to respond, and avoid people who are more likely to have adverse drug reactions. And so that therapeutic index of the balance between likely efficacy versus likely toxicity, genetics can really play into that and enable medications to be used where otherwise they might have failed.  This is most apparent I think in the cancer world. A classic example there, for example, is the development of a class of medications called EGFR inhibitors, which were developed for lung cancer, and in the initial cancer trials, actually were demonstrated to be ineffective, until people trialled them in East Asia and found that they were effective, and that that turns out to be because the type of cancers that respond to them are those that have mutations in the EGFR gene, and that that's common in East Asians. We now know that, wherever you are in the world, whether you're East Asian or European or whatever, if you have a lung adenocarcinoma with an EGFR mutation, you're very likely to respond to these medications. And so that pharmacogenomic discovery basically rescued a class of medication which is now probably the most widely used medication for lung adenocarcinomas, so a huge beneficial effect. And that example is repeated across multiple different cancer types, cancer medication types, and I'm sure in other fields we'll see that with expansive new medications coming in for molecularly targeted therapies in particular.  Vivienne: So, smaller and more effective trials rather than larger trials that perhaps seem not to work but actually haven't been tailored enough to the patients that are most likely to benefit.  Matt: Yeah, well, particularly now that drug development programmes tend to be very targeted at specific genetic targets, pharmacogenetics is much more likely to play a role in identifying patients who are going to respond to those medications. So, I think many people in the drug development world would like to see that, for any significant drug development programme, there's a proper associated pharmacogenomic programme to come up with molecular markers predicting a response.  Vivienne: We're going to wrap up there. Thank you so much to our guests, Bill Newman, Anita Hanson, Matt Brown, and our patient Jane Burns. Thank you so much for joining us today to discuss pharmacogenomics in personalised medicine, and the benefits, the challenges and the future prospects for integrating pharmacogenomics into healthcare systems. And if you'd like to hear more podcasts like this, please subscribe to Behind the Genes. It's on your favourite podcast app. Thank you so much for listening. I've been your host, Vivienne Parry. This podcast was edited by Bill Griffin at Ventoux Digital and produced by the wonderful Naimah. Bye for now. 

Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/41033 At the conclusion of this activity, participants will be able to: 1. Identify the research that led to the approval of genomic cancer for prostate cancer and the implementation of advanced imaging for prostate cancer. 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation. 3. State the National Comprehensive Cancer Network Guidelines for genomic testing and advanced imaging for prostate cancer. 4. Discern the different prognostic end points provided by various genomic tests. 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

This podcast episode dives into the screening and management of Duchenne muscular dystrophy, as well as diversity in genetic databases, and treating neuromuscular disorders. Jonathan is joined by Madhuri Hegde, Senior Vice-President & Chief Scientific Officer at Revvity, Inc., to talk about innovation in genomic testing. Use the following timestamps to navigate our episode!   (00:00)-Introduction  (03:54)-Entering into genomic technologies (05:13)-Duchenne muscular dystrophy (10:47)-Revvity and genome sequencing (13:13)-Ultrarapid genomic testing (urWGS) (15:18)-LANTERN project (17:42)-Lack of diversity in genetic databases (20:06)-New developments in genetics (22:19)-COVID-19 testing laboratories (27:27)-Madhuri's wishes for healthcare

We're digging into genetic testing to improve pregnancy success and prevent or decrease the risk of pregnancy loss. At Fab Fertile, we've been offering genetic/genomic testing as part of our method for years. This genetic testing is very different from the testing you would receive from your conventional doctor. Our genetic testing looks at specific gene variants and makes specific diet/lifestyle recommendations and supplements that can support your genes. Your genes are not your destiny, and there are targeted steps you can take to optimize your fertility and pregnancy success. I'm excited to announce that we have an even better genetic test that helps improve pregnancy outcomes. Designed to improve preconception health, birth outcomes, recurrent miscarriage, gestational diabetes and preeclampsia, the GrowBaby test identifies pathways that need support and helps us determine a customized plan based on your DNA. I'm excited to welcome Helen Gautschi to the podcast. Helen is a registered dietician (SA) and holds a Bachelor of Science in Dietetics (Honours) degree from Stellenbosch University in South Africa. She is also the Head of Research and Development and Education at DNAlife, which offers the GrowBaby genetic test.   In this episode, you'll learn: 1) How the GrowBaby test can improve birth outcomes and decrease the risk for preeclampsia and gestational hypertension and diabetes and miscarriage or pregnancy loss 2) How to support each pathway with specific diet/lifestyle and supplement recommendations 3) Why the preconception period is critical and specific steps you can take to improve healthy birth outcomes   --- RESOURCES: Fab Fertile Method https://www.fabfertile.com/what-we-do/   Ultimate Guide to Getting Pregnant This Year If You Have Low AMH/High FSH - https://fabfertile.clickfunnels.com/optinvbzjfsii   Ultimate Diet for Egg and Sperm Health - https://fabfertile.com/blogs/podcasts/the-ultimate-diet-for-egg-and-sperm-health   Want to Get Pregnant This Year - https://fabfertile.com/blogs/podcasts/want-to-get-pregnant-this-year   Top Fertility Supplements You Need To Get Pregnant This Year - Access your free guide here at www.suppguideffl.com   --- Where should I start to optimize pregnancy success? Get started with the Fertility Preparation Bundle (US residents only) here https://fabfertile.com/products/fertility-preparation-bundle and use code LAUNCH15 to save 15%.   --- Get your free copy of our Spring Fertility Recipe Guide (includes 5-day meal plan/grocery shopping list, all free from the TOP allergens) at https://www.fertilitydietfreebie.com/.    --- Join my FREE Facebook group and get my training on HOW to improve pregnancy success with your own eggs. https://www.facebook.com/groups/451444518397946   --- Check out https://www.fabfertile.com/blogs/podcasts/why-genomic-testing-can-help-with-recurrent-pregnancy-loss-birth-outcomes-and-preconception-health/   ---   Please note when promoting a product, we only select products that either Sarah Clark or her team has tried and believe are beneficial for someone who is TTC. We may receive a small commission.

What role does genomic testing play in promoting better health? While many are familiar with genetic tests like the BRCA mutation test, there's a growing trend towards testing for overall health improvement and personalisation of care. However, the question arises: is this approach advisable?Online services now offer tests where individuals swab the inside of their cheeks, but what happens next with the results? The surge in glucose testing is notable, but discussions increasingly focus on personalised genetic tests such as genomic testing. These tests provide insights into how our biology functions and how we can leverage this information to positively impact and enhance our health. From how we metabolise oestrogen to why some of us are better sleepers than others - is it all in our genes?In today's episode, I speak to cancer survivor, nutritional scientist and integrative oncology practitioner Toral Shah. We talk personal experiences and Toral will share with you how genomic testing can help you better understand your biology.You can find out more about Toral here: https://www.theurbankitchen.co.uk/ Here is the link to LifecodeGX https://www.lifecodegx.com/ and they share more information about the genomic testing. You cannot book directly but through a practitioner.Episode Highlights:00:00 Intro05:58 Genetic code influences our health, individual variations.07:52 Genetic testing, cancer risk, and epigenetic discussed.11:08 Genetic mutation has an impact on family and potentially daughters.13:50 Testing glucose responses to different foods is important.22:31 Genetic testing reveals family's shared cancer risk.28:52 Genomic testing requires practitioner input, diversity needed.31:17 We need genetic counselling in healthcare settings.34:16 Cancer diagnosis can be a transformative moment.About Dani:The Menopause and Cancer Podcast is hosted by Dani Binnington, menopause guide, patients advocate for people in menopause after a cancer diagnosis, and founder of the online platform Healthy Whole Me. There is lots of information out there about the menopause but hardly any if you have had a cancer diagnosis as well. Many people say to me they have no idea what their options are, who to ask for help, and that they feel really isolated in their experiences. I started this podcast because there was nothing out there when I was thrown into surgical menopause at the age of 39, which followed on from my cancer diagnosis aged 33.Through the episodes, I want to create more awareness, share information from our fabulous guest experts, doctors and other specialists in the cancer and menopause field. And of course, I will share stories from the people in our community.So that together we can work towards a better menopause experience. For all of us.More educated, better informed and less alone.

In this explainer episode, we've asked Ellen Thomas, Interim Chief Medical Officer at Genomics England, to explain what genetic and genomic tests are, why someone might do a test, and how they are performed, in less than 10 minutes. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, feel free to contact us on info@genomicsengland.co.uk. You can read the transcript below or download it here: https://files.genomicsengland.co.uk/documents/Podcast-transcripts/005-What-is-genetic-or-genomic-testing.docx Naimah: What is genetic or genomic testing? Today, I'm joined by Ellen Thomas, interim chief medical officer for Genomics England, who's going to explain more. So, first of all Ellen, what is a genetic test?   Ellen: Well, genetic tests examine a person's genes to see if they have any changes in their DNA which might explain their symptoms. We all have DNA in most of the cells of our bodies, we inherit it from our parents and pass it on to our children. DNA provides the blueprint for our genes, and the proteins which build and run our bodies. Nearly all of our DNA is exactly the same across all of us, but around 5 million out of our 3 billion DNA letters are different, and each of these we call a genetic variant. The pattern of genetic variants that we all carry helps to make us who we are, and genetic testing is designed to examine some of these variants to help inform our healthcare.   Naimah: So, why are they sometimes called genetic tests and sometimes called genomic tests?   Ellen: Well, the words genetic and genomic are often used in exactly the same way, but broadly, genetic tests are usually used to look at just one or a small number of a patient's genes, while a genomic test will look at hundreds or even thousands of genes at the same time. In general, it's fine to use either.   Naimah: If you want to hear more about the difference between genetics and genomics, you can find another explainer episode with Rich Scott on our website, which goes into more detail.   Okay, so coming back to you, Ellen, what are the reasons we might do a genomic test?   Ellen: Some rare health conditions are caused by DNA variants in our genes, conditions such as cystic fibrosis, Huntington's disease or sickle cell disease. In these 3 conditions, there is usually just one gene that is responsible, the same gene for all patients. That means that you can often find the DNA variant which has caused a patient's symptoms by doing a test which looks just at that gene, or even sometimes just at a part of the gene. But for other genetic conditions, a variant could be found in any of dozens or even hundreds of genes, which could cause the same condition or a group of conditions, and examples of that include familial forms of epilepsy or developmental disorders in children.   For these conditions, to find an answer you often need to do a broader genomic test, looking at many genes at the same time, and also sometimes in between the genes. Finding the variant in a patient's DNA which has caused the condition is useful, because it helps understand how the condition is passing down in the family, and whether it could affect anyone else in the family in the future. It is also increasingly used to work out which treatment an individual patient might respond to best.   Genomic tests are also used to help diagnose and treat cancer. A tumour develops and spreads because new variants in the DNA build up inside the tumour, which are not present in the patient's healthy cells. By testing the DNA of the tumour, you can sometimes understand more about why it happened and what treatment might be most effective.   Naimah: So, can you tell me a bit about what sort of questions you can and can't address with genomic testing, and how has this changed over time?   Ellen: Well, at the most basic level, if a condition is not caused by DNA variants, then a genomic test will not provide any useful information. So, doctors use genomic tests when they suspect that a patient might have an explanation of their symptoms in their genes, but we don't always find an answer. Sometimes patients with a genomic cause and those with a different cause may have very similar symptoms.   We do constantly learn more about the ways in which genetic variants cause disease through research. Patients may have a gene variant causing their condition, but it's so rare that it hasn't yet been discovered, or so complex that it can't be seen in the test analysis, so the test won't identify the cause. Sometimes new understanding through research can then find the answer, which can be many years after the patient first developed symptoms.   Naimah: And how are these tests performed? For example, are they a blood sample?   Ellen: Yes, for most rare conditions, the tests use a blood sample. In cancers, a sample of the tumour needs to be tested after it's removed by surgery or biopsy. The blood or the tumour is then processed to extract the DNA, and then there's a range of different tests which can be used to read the DNA sequence. Expert scientists in the NHS then review variants in the DNA to make sense of the results and provide information to clinicians and patients about what it means for their diagnosis or treatment.   Naimah: And why are there lots of different genomic tests which can be used in healthcare?   Ellen: There are different types of genetic variants, and there are tests available that are specialised for these different types of genetic variant. Some tests look at a single gene, some tests look at many genes, often known as a panel of genes. Some also compare genomic information from a patient and their parents to understand which DNA variants are likely to be important. The tests will be selected to match what is understood about the patient's symptoms and their likely cause, and to provide the best chance of finding information which will be useful for their care.   Naimah: That was Ellen Thomas explaining genetic and genomic testing. If you'd like to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk. Thank you for listening. 

In this episode, host Shikha Jain, MD, speaks with Barnaby Balmforth, PhD, about the evolution of genomics in cancer care, the impact of personalized care tools and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Balmforth 1:12 •    The interview 3:01     •    How did you get to where you are today? What drove you to become a leader in this space? 3:45 •    What is genomics, and why is genomic analysis important in cancer care? 7:18 •    Jain and Balmforth on the evolution of technology and challenges facing genomics and diagnostic testing to achieve personalized care for individual patients. 11:59 •    In addition to time, can you speak on the challenge of access for this type of technology?  13:20 •    How have you been able to implement “next day” test results and reports of your technology? 17:50  •    Jain and Balmforth on how Biofidelity's technology can transform the delivery of care, as well as its psychological and mental impact. 19:06 •    What's coming down the line for you and Biofidelity?  20:56 •    What are your thoughts for when you expand beyond thoracic oncology? What are your long-term visions for other disease sites?  24:19 •    Do you have any thoughts on AI and how it may influence genomics in cancer care?  25:51 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:37 •    How to contact Balmforth 30:37 •    Thanks for listening 31:10 Barnaby Balmforth, PhD, is co-founder and CEO of Biofidelity. Barnaby has more than 15 years' experience in the leadership of multidisciplinary technology development. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Balmforth can be reached via the Biofidelity website. Disclosures: Jain reports no relevant financial disclosures. Balmforth reports he is an employee of Biofidelity and owns shares in the company.

Season 7 || Episode 11 Have you heard these myths about genomic testing in cattle? 1. Genomic testing is only for seedstock producers. 2. Genomic testing is too complex and time-consuming for commercial producers. 3. Genomic testing doesn't provide practical benefits for commercial operations. Nick Hammett and host Shaye Wanner bust these myths and dive into practical ways you can use genomics as a commercial cow-calf producer. In this episode, you will be able to: Uncover the potential of genomic testing to improve your cattle breeding strategies and boost profitability. Harness the power of genomic data to make more informed and effective mating decisions for your cattle operation. Discover what traits are analyzed in the Igenity Beef Test and how to use these when selecting replacement heifers Learn how genomic data helps build relationships with cattle buyers Cultivate patience as a key virtue in the genetic selection process to achieve long-term success in your cattle breeding endeavors. Learn more about Igenity Beef https://www.neogen.com/igenity-beef My special guest is Nick Hammett Nick Hammett, currently serving as a key accounts manager at Neogen, brings substantial expertise in the beef industry. With a background that includes working for breed associations, a vertically integrated beef company, and a large commercial cow-calf operation, Nick has acquired a comprehensive understanding of the industry. His role involves assisting commercial cattle producers in making well-informed breeding decisions and improving the productivity of their operations. Nick's proficiency in genomic testing and its practical applications for commercial producers positions him as a knowledgeable authority for anyone seeking to enhance their breeding strategies and bolster profitability within the beef industry. The key moments in this episode are: 00:00:01 - Introduction to casual cattle conversations 00:01:04 - Benefits of genomic testing 00:07:37 - Value of genomics for commercial producers 00:10:38 - Future of genomic information in the industry 00:12:07 - Leveraging genomic information for bull decisions 00:13:53 - Understanding Genomic Scores 00:15:03 - Importance of Genomic Scores 00:16:30 - Database Comparison and Selection Decisions 00:18:07 - Sample Collection and Process 00:19:52 - Using Indexes for Decision-Making Links: Full Show Notes: https://www.casualcattleconversations.com/casual-cattle-conversations-podcast-shownotes  Free Weekly Resources: https://www.casualcattleconversations.com/ranching-resources  • The easiest way to create a new revenue stream for your ranch is with LandTrust. Learn more here! www.landtrust.com/a/cattleconvos  Take Your Ranch to the Next Level Once a month Shaye hosts Q&A calls between cattle producers and beef industry leaders to help ranchers find answers to their questions and improve their bottom lines. The best part is you get expert insight from the comfort of your own ranch and get to ask any question you want relating to the topic! Learn More About RancherMinds: https://www.casualcattleconversations.com/ranchermind-events  Connect with me on Social Media Facebook - https://www.facebook.com/cattleconvos Instagram - https://www.instagram.com/cattleconvos/ Podcast Coaching Do you have an existing podcast or want to start a new one but don't know where to start? Connect with Shaye and she will lay out everything you need to know to get you started on the right foot. Find podcast resources and coaching opportunities here! https://www.casualcattleconversations.com/podcast-coaching

In this episode, Dr. Edward Schaeffer, chair of urology at Feinberg School of Medicine, discusses precision medicine in prostate cancer with Dr. Aditya Bagrodia. First, Dr. Schaeffer introduces the importance of using a defined screening strategy for prostate cancer that includes analyzing a patient's genomic and germline risk. Then, he summarizes existing and new diagnostic tools for prostate cancer. Additionally, Dr. Schaeffer discusses genomic testing and PSMA testing and explains how he applies them to individual patient cases depending on their cancer stage and grade. Finally, the doctors highlight the ability of future tools, like PET PSMA scans, to advance precision medicine. --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/3XO8iL --- SHOW NOTES 00:00 - Introduction 10:32 - Precision Medicine and Prostate Cancer 16:17 - Screening and Diagnosis of Prostate Cancer 29:41 - Personalizing Surveillance and Disease Management 33:11 - The Role of Genomic Testing in Prostate Cancer 45:00 - The Use of PET PSMA Scans in Prostate Cancer Staging 48:08 - The Future of Precision Medicine in Prostate Cancer

View the Show Notes For This EpisodeGet Free Weekly Health Tips from Dr. HymanSign Up for Dr. Hyman's Weekly Longevity JournalGet Ad-free Episodes & Dr. Hyman+ Audio ExclusivesDr. Sharon Hausman-Cohen is the Chief Medical Officer and co-founder of IntellxxDNA and has been in the field of integrative medicine for over 25 years. She is the co-author of many publications and a textbook chapter on using genomics to improve outcomes in cognitive decline and autism.This episode is brought to you by Rupa Health, Fatty15, BiOptimizers, and ARMRA.Streamline your lab orders with Rupa Health. Access more than 3,000 specialty lab tests and register for a FREE live demo at RupaHealth.com.Fatty15 contains pure, award-winning C15:0 in a bioavailable form. Get an exclusive 10% off a 90-day starter kit subscription. Just visit Fatty15.com and use code DRHYMAN10 to get started.Tackle an overlooked root cause of stress with Magnesium Breakthrough. Visit bioptimizers.com/hyman and use code HYMAN10 to save 10% and receive free gifts with your purchase.Save 15% on your first order of ARMRA Colostrum and unlock the power of 400+ functional nutrients. Just visit TryARMRA.com/Mark or use code MARK.In this episode we discuss (audio version / Apple Subscriber version):What are genes and what do they do? (6:37 / 4:33)Genetic predisposition does not mean predestined (9:22 / 7:18)The difference between genetics vs genomics (13:10 / 11:06)Polygenic risk scoring for chronic disease (18:18 / 16:14)Dementia risk and treatment (33:59 / 29:24)Mental and cognitive health issues in children (46:00 / 41:25)The similarities between Autism and Alzheimer's patients (49:49 / 45:14)My genomic test results, specifically related to detoxification and osteoporosis (52:21 / 47:45)Genetic vs genomic testing (1:06:29 / 1:01:54)Learn more at IntellxxDNA.com. Hosted on Acast. See acast.com/privacy for more information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBrendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Faculty/PlannerBalazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBrendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Faculty/PlannerBalazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBrendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Faculty/PlannerBalazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBrendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Faculty/PlannerBalazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBrendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Faculty/PlannerBalazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBrendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Faculty/PlannerBalazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBrendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Faculty/PlannerBalazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Join us in an enlightening conversation with Mandana Kamgar, MD, MPH, a specialist with the Froedtert & The Medical College of Wisconsin health network, as we delve into the intricacies of neoadjuvant therapy in pancreatic cancer. This podcast offers a thorough exploration of treatment stages, the impact of early diagnosis, and cutting-edge advances in cancer care. Discover the nuances of genomic and genetic testing and how they shape personalized treatment plans. Learn about the challenges and triumphs in the journey towards effective pancreatic cancer treatment, providing hope and guidance to patients and caregivers alike. Chapters: Introduction to Neoadjuvant Therapy in Pancreatic Cancer (00:00:54) - A brief overview of the podcast's focus and the guest's background. Discussing the Latest Five-Year Survival Rate News (00:02:30) - Reflections on recent advancements in pancreatic cancer survival rates. The Importance of Simplified Communication for Caregivers (00:03:00) - Emphasizing the need for accessible information for caregivers and patients. Neoadjuvant Therapy 101: An In-Depth Explanation (00:06:02) - A detailed discussion on the role and process of neoadjuvant therapy in cancer treatment. The Stages of Pancreatic Cancer and Treatment Variations (00:14:22) - Understanding different stages of pancreatic cancer and corresponding treatment strategies. Advances in Pancreatic Cancer Research and Clinical Trials (00:19:07) - Insights into the latest research, trials, and molecular advancements in treatment. The Role of Genetic and Genomic Testing in Treatment (00:20:29) - Exploring how genetic profiling influences personalized treatment approaches. Challenges and Considerations in Neoadjuvant Therapy (00:27:31) - Discussing potential obstacles and critical factors in treatment planning. Final Thoughts and Advice for Patients and Caregivers (00:30:07) - Concluding advice for those affected by pancreatic cancer and highlighting additional resources. The Seena Magowitz Foundation. A 501(c)(3) nonprofit committed to the awareness, prevention, and cure of pancreatic cancer. It works to fund the leading edge of translational pancreatic cancer research. The Foundation focuses on the development and delivery of new treatments. The ultimate goal: eliminate this deadly killer. Federal ID# 20-4751072  --- Send in a voice message: https://podcasters.spotify.com/pod/show/seena-magowitz-foundation/message

In the latest episode of STtalks we sit down with Natalia Rodrigues, STgenetics-Canada Director of Sales and Operations and Evanil Campos, STgenetics-Brazil General Manager, to discuss the start of STgenetics Genomic Awards which took place first in Brazil and then in Canada. Within this episode we cover the value of genomic testing, how it can accelerate genetic progress and why this first of its kind celebration is important to STgenetics.

At the end of 2022, adagrasib received its first FDA approval for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer. Research is ongoing into adagrasib, a KRAS G12C inhibitor, for other tumors. In today's episode, we're joined by Jun Gong, MD, associate professor of medicine and the medical director of colorectal cancer in the Division of Medical Oncology at Cedars-Sinai Medical Center. During this interview, he discusses the mechanism of adagrasib, what other diseases it is being studied in, the latest data on adagrasib in colorectal cancer, and the importance of conducting genomic testing.

Dr. Barnaby Balmforth, Co-Founder and CEO of Biofidelity, has a mission to make genomic analysis simpler, faster, and more reliable for treatment decisions. Biofidelity addresses genome sequencing challenges by using a targeted approach and unique technology that allows for local testing using PCR rather than DNA sequencers. Thanks to COVID, an existing global infrastructure of PCR equipment provides an opportunity to target specific biomarkers and deliver actionable information to physicians and patients.   Barnaby explains, "The challenge as we see it is that in this modern oncology era, there is now a wide need for multi-gene genomic profiling of patients. The only solution that has been available to enable that is DNA sequencing. The media has quite widely covered how the genomics market is growing, and the cost of sequencing is shrinking. But sadly, in the clinical space, oncologists and patients are still failing to fully experience the benefits of this technology." "It is not a simple process to perform clinical diagnostics using DNA sequencing. That has resulted in the centralization of sequencing tests in very large laboratories with all of the associated logistical challenges of getting samples to those laboratories, processing them through these complex workflows, and then returning results to the clinicians." "We focus on delivering the clinically actionable information to physicians as quickly as possible. So, we are not forming very large whole genome sequencing tests. We are focused on what information is associated with approved therapies, what information is recommended for testing in the treatment guidelines, and what is needed to make these treatment decisions. So, we take a more focused and targeted approach." #Biofidelity #GenomicTesting #GenomeSequencing #Biomarkers #PCRInstruments biofidelity.com Download the transcript here

Dr. Barnaby Balmforth, Co-Founder and CEO of Biofidelity, has a mission to make genomic analysis simpler, faster, and more reliable for treatment decisions. Biofidelity addresses genome sequencing challenges by using a targeted approach and unique technology that allows for local testing using PCR rather than DNA sequencers. Thanks to COVID, an existing global infrastructure of PCR equipment provides an opportunity to target specific biomarkers and deliver actionable information to physicians and patients.   Barnaby explains, "The challenge as we see it is that in this modern oncology era, there is now a wide need for multi-gene genomic profiling of patients. The only solution that has been available to enable that is DNA sequencing. The media has quite widely covered how the genomics market is growing, and the cost of sequencing is shrinking. But sadly, in the clinical space, oncologists and patients are still failing to fully experience the benefits of this technology." "It is not a simple process to perform clinical diagnostics using DNA sequencing. That has resulted in the centralization of sequencing tests in very large laboratories with all of the associated logistical challenges of getting samples to those laboratories, processing them through these complex workflows, and then returning results to the clinicians." "We focus on delivering the clinically actionable information to physicians as quickly as possible. So, we are not forming very large whole genome sequencing tests. We are focused on what information is associated with approved therapies, what information is recommended for testing in the treatment guidelines, and what is needed to make these treatment decisions. So, we take a more focused and targeted approach." #Biofidelity #GenomicTesting #GenomeSequencing #Biomarkers #PCRInstruments biofidelity com Listen to the podcast here

Julie Stevens (https://www.mojohealth.org/) and Oscar Sierra delve into the transformative power of genomic testing for cancer patients. They emphasize the importance of genomic testing in measuring incremental data to understand treatment efficacy and tailor interventions. Tune in to learn how data-driven strategies can improve cancer care as they advocate for changing the goals of cancer treatment to focus on long-term quality of life and survival. In this episode, Julie and Oscar discuss: 1. The importance of genomic testing in measuring incremental change in cancer treatment. 2. The differences between genomic and genetic testing. 3. The complexities of cancer pathology and the need for tailored treatments. 4. Challenges patients face in obtaining genomic testing. 5. Recommendations for reputable genomic testing companies. 6. The significance of data-driven strategies in improving cancer care. Connect with Julie Stevens and the Mojo Movement:  Instagram: https://instagram.com/mojohealthorg  TikTok: https://tiktok.com/@mojohealthorg  YouTube: https://www.youtube.com/@mojohealth  Facebook: https://facebook.com/mojohealthorg  Website: https://www.mojohealth.org/ Links Mentioned: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830511/ For an appointment with Oscar from Sierra Botanica and Collaborative: https://www.sierracollaborativemed.com/ DISCLAIMER: The views, thoughts, and opinions expressed on this podcast are the speaker's own and do not represent the views, thoughts, and opinions of MOJO Health Cooperative LLC, a Georgia Limited Liability Company, its respective officers, directors, employees, agents, or representatives. This podcast is presented by MOJO Health Cooperative, and cannot be copied or rebroadcast without consent. The material and information presented here is for general information purposes only, and not intended to supplant the expert advice and/or consultation of a medical doctor and/or a licensed physician, and/or an attorney. In short, this podcast is not intended to replace professional medical advice, nor legal advice. The "MOJO Health" name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service. Again, none of the content of this podcast should be considered legal advice, nor medical advice. As always, consult a lawyer and/or a licensed physician in lieu of relying upon the advice of any of the participants of this podcast. The host(s) of this podcast are not licensed lawyers, physicians, doctors of osteopath, nor medical doctors in any jurisdiction anywhere. The host(s) of this podcast do not practice medicine and do NOT profess to be able to do any of the following: (1) diagnose, heal, treat, prevent, prescribe for, or removing any physical, mental, or emotional ailment or supposed ailment of an individual; (2) engage in the end of human pregnancy; (3) treat human ailments; nor (4) perform acupuncture. MOJO Health Cooperative LLC is not responsible for any losses, damages, or liabilities that may arise from the use of this podcast.

What if you could choose not to impart a hereditary condition to your newborn before they were born. Would you take that option? Pre-implantation genetic testing (PGT) is a technique used to test embryos for known genetic conditions or chromosomal abnormalities.  From physical health conditions all the way to mental health, Dylan and Angus are presented which two unique cases of a new IVF program called ‘Genomic Testing' and the ethics around how far should you go when creating a "super baby" and the inherent ableism of the parents to create a "Healthy Baby". Angus also has an exciting family news himself he shares with you, the ListenABLE family! Link to VICE News Article: https://www.youtube.com/watch?v=KthrLReQE70 Join the 10,000+ legends on Instagram: @ListenABLE_ Podcast https://www.instagram.com/listenable_podcast/ Grab our first merch release at our website From Your Pocket https://fromyourpocket.com.au/work/listenable/merch  See omnystudio.com/listener for privacy information.

Our special guest, Dr. Paul Krushka, Chief Medical Officer for Gene DX, guides us through this fascinating journey, explaining how Gene DX is revolutionizing the medical world with advanced genetic testing. Hear about the impressive strides made in detecting rare genetic diseases using whole-exome and whole-genome sequencing. He enlightens us about the importance of understanding variants in genetic testing and how to easily order tests through GeneDx. Hear insights into the potentially game-changing Guardian Study. This collaborative effort amongst Columbia University, Illumina, and the New York State Department of Health could significantly shorten the diagnostic journey for many patients, bringing a new dawn in genetic testing. This episode is a must for anyone longing to understand the future of genomic testing. As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In recent years, there has been a major influx of new genetic tests that have hit the market. While these tests promise to revolutionize diagnostics and treatment decision-making, the industry needs to overcome a variety of reimbursement and logistical barriers to achieve any goals for genomics at scale. In this episode, guest host and Advisory Board expert partner Devin Airey invites Mark Gardner, the SVP of Genomic Medicine and Oncology at Quest Diagnostics, and Dan Edelstein, President and CEO of Haystack Oncology, to discuss their vision for genomics at scale. Throughout the conversation, they discuss increased attention from providers and purchasers, how to integrate new genomics technology into patient care, and how to address opportunities and concerns in the market. Links: 6 questions shaping the future of oncology screening and diagnostics What liquid biopsies could mean for cancer treatment and disease monitoring Home | Quest Diagnostics Haystack Oncology – Better decisions with better MRD testing Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio [Webinar] Consumer insights decision makers should lead with in 2023 (August 24 | 3-4pm ET)

Join Dr. Rick Baehner, Chief Medical Officer of the Precision Oncologydivision at Exact Sciences, in this episode of Becker's Healthcare Podcast. Dr.Baehner discusses the evolving landscape of precision oncology and how ExactSciences is equipped to address the dynamic challenges and opportunities inmolecular testing for cancer patients. He shares key milestones that highlight thecompany's commitment to innovation. Exploring the role of technology in cancerprevention, early detection, and improved treatment guidance, Dr. Baehner explainshow Exact Sciences aligns with these objectives while addressing the concerns ofcancer leaders. Discover what exciting goals and developments are on the horizonfor Exact Sciences and tune in for Dr. Baehner's closing thoughts on this insightfuljourney.This episode is sponsored by Exact Sciences.Cologuard is intended to screen adults 45 and older at average risk for colorectalcancer. Rx only. Please see Cologuard Indications and Important Risk Information atCologuardhcp.com/risk-information. Exact Sciences' MCED and MRD tests are underdevelopment. The features discussed in this podcast describe current developmentgoals. It has not been cleared or approved by the US Food and Drug Administrationor any other national regulatory authority.